147 related articles for article (PubMed ID: 9523171)
1. Prevention of renal injury in diabetic MWF rats by angiotensin II antagonism.
Remuzzi A; Fassi A; Sangalli F; Malanchini B; Mohamed EI; Bertani T; Remuzzi G
Exp Nephrol; 1998; 6(1):28-38. PubMed ID: 9523171
[TBL] [Abstract][Full Text] [Related]
2. [The effect of angiotensin-converting enzyme inhibitors on the progression of chronic renal failure].
Bernadet-Monrozies P; Rostaing L; Kamar N; Durand D
Presse Med; 2002 Nov; 31(36):1714-20. PubMed ID: 12467154
[TBL] [Abstract][Full Text] [Related]
3. Effect of angiotensin II antagonism on the regression of kidney disease in the rat.
Remuzzi A; Gagliardini E; Donadoni C; Fassi A; Sangalli F; Lepre MS; Remuzzi G; Benigni A
Kidney Int; 2002 Sep; 62(3):885-94. PubMed ID: 12164870
[TBL] [Abstract][Full Text] [Related]
4. Additive effect of ACE inhibition and angiotensin II receptor blockade in type I diabetic patients with diabetic nephropathy.
Jacobsen P; Andersen S; Jensen BR; Parving HH
J Am Soc Nephrol; 2003 Apr; 14(4):992-9. PubMed ID: 12660333
[TBL] [Abstract][Full Text] [Related]
5. Renoprotective effects of valsartan and enalapril in STZ-induced diabetes in rats.
Kalender B; Oztürk M; Tunçdemir M; Uysal O; Dagistanli FK; Yegenaga I; Erek E
Acta Histochem; 2002; 104(2):123-30. PubMed ID: 12086332
[TBL] [Abstract][Full Text] [Related]
6. Role of angiotensin II and bradykinin in experimental diabetic nephropathy. Functional and structural studies.
Allen TJ; Cao Z; Youssef S; Hulthen UL; Cooper ME
Diabetes; 1997 Oct; 46(10):1612-8. PubMed ID: 9313758
[TBL] [Abstract][Full Text] [Related]
7. Comparison of the effects of angiotensin-converting enzyme inhibition and angiotensin II receptor blockade on the evolution of spontaneous glomerular injury in male MWF/Ztm rats.
Remuzzi A; Malanchini B; Battaglia C; Bertani T; Remuzzi G
Exp Nephrol; 1996; 4(1):19-25. PubMed ID: 8788596
[TBL] [Abstract][Full Text] [Related]
8. Additive effects of cilnidipine and angiotensin II receptor blocker in preventing the progression of diabetic nephropathy in diabetic spontaneously hypertensive rats.
Aritomi S; Niinuma K; Ogawa T; Konda T; Nitta K
Clin Exp Nephrol; 2013 Feb; 17(1):41-50. PubMed ID: 23011292
[TBL] [Abstract][Full Text] [Related]
9. Blocking angiotensin II ameliorates proteinuria and glomerular lesions in progressive mesangioproliferative glomerulonephritis.
Nakamura T; Obata J; Kimura H; Ohno S; Yoshida Y; Kawachi H; Shimizu F
Kidney Int; 1999 Mar; 55(3):877-89. PubMed ID: 10027924
[TBL] [Abstract][Full Text] [Related]
10. Valsartan and the kidney: present and future.
Mann JF
J Cardiovasc Pharmacol; 1999; 33 Suppl 1():S37-40; discussion S41-3. PubMed ID: 10028953
[TBL] [Abstract][Full Text] [Related]
11. Effects of combined ACE inhibitor and angiotensin II antagonist treatment in human chronic nephropathies.
Campbell R; Sangalli F; Perticucci E; Aros C; Viscarra C; Perna A; Remuzzi A; Bertocchi F; Fagiani L; Remuzzi G; Ruggenenti P
Kidney Int; 2003 Mar; 63(3):1094-103. PubMed ID: 12631093
[TBL] [Abstract][Full Text] [Related]
12. Effects of the angiotensin II antagonist valsartan on blood pressure, proteinuria, and renal hemodynamics in patients with chronic renal failure and hypertension.
Plum J; Bünten B; Németh R; Grabensee B
J Am Soc Nephrol; 1998 Dec; 9(12):2223-34. PubMed ID: 9848776
[TBL] [Abstract][Full Text] [Related]
13. Safety of the combination of valsartan and benazepril in patients with chronic renal disease. European Group for the Investigation of Valsartan in Chronic Renal Disease.
Ruilope LM; Aldigier JC; Ponticelli C; Oddou-Stock P; Botteri F; Mann JF
J Hypertens; 2000 Jan; 18(1):89-95. PubMed ID: 10678548
[TBL] [Abstract][Full Text] [Related]
14. The renoprotective properties of angiotensin-converting enzyme inhibitors in a chronic model of membranous nephropathy are solely due to the inhibition of angiotensin II: evidence based on comparative studies with a receptor antagonist.
Zoja C; Donadelli R; Corna D; Testa D; Facchinetti D; Maffi R; Luzzana E; Colosio V; Bertani T; Remuzzi G
Am J Kidney Dis; 1997 Feb; 29(2):254-64. PubMed ID: 9016898
[TBL] [Abstract][Full Text] [Related]
15. Vascular hypertrophy and albumin permeability in a rat model combining hypertension and diabetes mellitus. Effects of calcium antagonism, angiotensin converting enzyme inhibition, and angiotensin II-AT1-receptor blockade.
Hulthén UL; Cao Z; Rumble JR; Cooper ME; Johnston CI
Am J Hypertens; 1996 Sep; 9(9):895-901. PubMed ID: 8879346
[TBL] [Abstract][Full Text] [Related]
16. Additive hypotensive effect of angiotensin-converting enzyme inhibition and angiotensin-receptor antagonism in essential hypertension.
Stergiou GS; Skeva II; Baibas NM; Roussias LG; Kalkana CB; Achimastos AD; Mountokalakis TD
J Cardiovasc Pharmacol; 2000 Jun; 35(6):937-41. PubMed ID: 10836730
[TBL] [Abstract][Full Text] [Related]
17. Disparate effects of angiotensin II antagonists and calcium channel blockers on albuminuria in experimental diabetes and hypertension: potential role of nephrin.
Davis BJ; Cao Z; de Gasparo M; Kawachi H; Cooper ME; Allen TJ
J Hypertens; 2003 Jan; 21(1):209-16. PubMed ID: 12544453
[TBL] [Abstract][Full Text] [Related]
18. The role of angiotensin II antagonism in type 2 diabetes mellitus: a review of renoprotection studies.
Zanella MT; Ribeiro AB
Clin Ther; 2002 Jul; 24(7):1019-34. PubMed ID: 12182249
[TBL] [Abstract][Full Text] [Related]
19. Renoprotective and anti-hypertensive effects of combined valsartan and perindopril in progressive diabetic nephropathy in the transgenic (mRen-2)27 rat.
Wilkinson-Berka JL; Gibbs NJ; Cooper ME; Skinner SL; Kelly DJ
Nephrol Dial Transplant; 2001 Jul; 16(7):1343-9. PubMed ID: 11427623
[TBL] [Abstract][Full Text] [Related]
20. Dissociation between antiproteinuric and antihypertensive effect of angiotensin converting enzyme inhibitors in rats.
Remuzzi A; Imberti O; Puntorieri S; Malanchini B; Macconi D; Magrini L; Bertani T; Remuzzi G
Am J Physiol; 1994 Dec; 267(6 Pt 2):F1034-44. PubMed ID: 7528985
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
